Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Cresset Asset Management LLC

Cresset Asset Management LLC cut its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 49.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,843 shares of the specialty pharmaceutical company's stock after selling 16,606 shares during the quarter. Cresset Asset Management LLC's holdings in Jazz Pharmaceuticals were worth $2,074,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. LSV Asset Management raised its holdings in Jazz Pharmaceuticals by 1.5% during the fourth quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company's stock valued at $311,699,000 after acquiring an additional 37,108 shares during the period. Pacer Advisors Inc. raised its holdings in Jazz Pharmaceuticals by 5.5% during the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock valued at $272,713,000 after acquiring an additional 115,102 shares during the period. Dimensional Fund Advisors LP raised its holdings in Jazz Pharmaceuticals by 18.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock valued at $250,619,000 after acquiring an additional 320,724 shares during the period. Capital World Investors raised its holdings in Jazz Pharmaceuticals by 5.7% during the fourth quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company's stock valued at $236,860,000 after acquiring an additional 104,195 shares during the period. Finally, Ameriprise Financial Inc. raised its holdings in Jazz Pharmaceuticals by 20.9% during the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock valued at $225,076,000 after acquiring an additional 315,608 shares during the period. 89.14% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on JAZZ shares. UBS Group raised Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price target for the company from $145.00 to $179.00 in a report on Friday, March 7th. Wells Fargo & Company raised Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. Cantor Fitzgerald cut Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and lifted their target price for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Piper Sandler reaffirmed an "overweight" rating and issued a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Finally, JPMorgan Chase & Co. lifted their price target on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $182.79.

Jazz Pharmaceuticals Trading Up 5.9%

Shares of NASDAQ:JAZZ traded up $5.80 during trading hours on Monday, hitting $103.58. 1,659,789 shares of the company's stock traded hands, compared to its average volume of 836,767. Jazz Pharmaceuticals plc has a 1 year low of $95.49 and a 1 year high of $148.06. The business has a fifty day moving average price of $118.23 and a 200-day moving average price of $122.25. The firm has a market capitalization of $6.38 billion, a P/E ratio of 14.59, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The business had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. During the same quarter last year, the firm earned $2.68 EPS. The firm's quarterly revenue was down .5% on a year-over-year basis. Equities analysts expect that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current year.

Insider Activity at Jazz Pharmaceuticals

In related news, CMO Robert Iannone sold 7,080 shares of the business's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $138.60, for a total value of $981,288.00. Following the completion of the sale, the chief marketing officer now owns 82,024 shares in the company, valued at approximately $11,368,526.40. The trade was a 7.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bruce C. Cozadd sold 6,500 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $144.25, for a total transaction of $937,625.00. Following the completion of the transaction, the chief executive officer now directly owns 464,058 shares of the company's stock, valued at $66,940,366.50. This trade represents a 1.38% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,236 shares of company stock worth $3,956,190. Company insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.